Our Pricing

Wegovy vs Mounjaro: Maintenance Dose Options UK

Published on: June 03, 2026

Understanding wegovy vs mounjaro maintenance dose uk options is crucial for sustaining weight loss after reaching your goal. At Cured Pharmacy, our UK-registered clinical team helps patients transition to appropriate maintenance strategies with both tirzepatide and semaglutide treatments, ensuring long-term success through evidence-based dosing protocols.

What Is a Maintenance Dose in Weight Loss Treatment?

A maintenance dose refers to the lowest effective dose of medication needed to sustain your achieved weight loss without further significant reduction. Unlike the titration phase where doses gradually increase to reach therapeutic levels, maintenance dosing focuses on preventing weight regain whilst minimising side effects and treatment costs [1].

Clinical evidence demonstrates that discontinuing GLP-1 receptor agonists after reaching goal weight typically results in substantial weight regain within 12 months [2]. This is why UK prescribers increasingly recommend ongoing maintenance therapy rather than stopping treatment entirely once targets are met.

Both Mounjaro and Wegovy require individualised maintenance strategies. Your UK prescriber will assess factors including weight stability, tolerability, metabolic health markers, and personal preferences when determining your optimal long-term dose.

Wegovy Maintenance Dose Options After Goal Weight

Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The standard maximum dose is 2.4mg weekly, achieved through a structured titration schedule over 16-20 weeks [3].

Once patients reach their goal weight on the 2.4mg dose, UK prescribers may consider several maintenance approaches. Some patients continue the full 2.4mg dose indefinitely to prevent regain, whilst others successfully maintain weight loss on lower doses such as 1.7mg or even 1mg weekly, particularly if side effects were problematic at higher doses.

In the STEP-4 trial, participants who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight within the following year, whilst those who continued treatment maintained their weight loss [2]. This underscores the importance of ongoing therapy rather than stopping medication after achieving initial goals.

Typical Wegovy Maintenance Protocols

Most UK prescribers recommend staying on the 2.4mg maintenance dose for at least 6-12 months after reaching goal weight to allow metabolic adaptation. After this stabilisation period, some patients trial dose reduction to 1.7mg or 1mg weekly whilst monitoring weight closely. If weight begins creeping upward by more than 2-3% over 4-8 weeks, the dose is typically increased back to the previous level. This personalised approach balances efficacy, tolerability, and cost-effectiveness for long-term weight management.

Mounjaro Maintenance Dose Strategies

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that produces greater average weight loss than semaglutide-based treatments. The maximum licensed dose is 15mg weekly, with some patients achieving their goals on intermediate doses of 7.5mg, 10mg, or 12.5mg [4].

Maintenance dosing with Mounjaro follows similar principles to Wegovy but with additional flexibility due to the wider dose range. Patients who reach goal weight on 15mg may continue that dose, or work with their prescriber to trial stepping down to 12.5mg or 10mg whilst monitoring weight stability over 8-12 week intervals.

The SURMOUNT-4 trial demonstrated that participants who discontinued tirzepatide after achieving weight loss regained approximately 14% of body weight over 52 weeks, compared to those who continued treatment and lost an additional 5.5% [5]. This reinforces that maintenance therapy is essential for sustained results with Mounjaro, just as with other GLP-1 treatments.

Finding Your Optimal Mounjaro Maintenance Dose

Individual maintenance doses vary considerably based on metabolic factors, lifestyle habits, and treatment response. Some patients maintain excellent weight stability on 7.5mg weekly, whilst others require 12.5mg or 15mg to prevent regain. Your UK prescriber will recommend regular monitoring during the first 6-9 months after reaching goal weight, adjusting doses based on weight trends, side effect profile, and blood glucose markers if relevant. The goal is identifying the lowest effective dose that maintains your weight loss without causing problematic side effects or excessive ongoing costs.

Wegovy vs Mounjaro: Direct Maintenance Comparison

When comparing maintenance strategies between these two treatments, several factors warrant consideration. Mounjaro typically produces greater total weight loss during the active treatment phase, with patients in the SURMOUNT-1 trial losing an average of 22.5% body weight on the 15mg dose compared to approximately 14.9% with Wegovy 2.4mg in STEP trials [4][3].

However, maintenance dosing success depends less on which medication produces greater initial weight loss and more on individual tolerability, adherence, and metabolic response. Some patients tolerate semaglutide better with fewer gastrointestinal side effects, whilst others find tirzepatide's dual mechanism more effective for appetite control during maintenance.

Cost considerations also influence long-term maintenance decisions. At Cured Pharmacy, Mounjaro starts from £124.99 and requires clinical assessment to determine your appropriate dose. Your UK prescriber will discuss both clinical effectiveness and practical sustainability when recommending a maintenance strategy tailored to your circumstances.

Can You Switch Between Wegovy and Mounjaro During Maintenance?

Switching between GLP-1 treatments during the maintenance phase is possible under appropriate clinical supervision. Some patients initially achieve weight loss with one medication but switch to another for maintenance due to tolerability issues, supply constraints, or cost considerations.

When transitioning from Wegovy to Mounjaro or vice versa, UK prescribers typically start at an equivalent or slightly lower dose to assess tolerability before adjusting upward if needed. For example, a patient stable on Wegovy 2.4mg might begin Mounjaro at 7.5mg or 10mg weekly, whilst someone on Mounjaro 15mg switching to Wegovy would likely start at the maximum 2.4mg dose.

The decision to switch medications should always involve careful discussion with your prescriber. Factors including your weight stability, side effect history, metabolic health markers, and treatment goals all inform whether switching is appropriate or whether continuing your current medication at an adjusted dose makes more clinical sense.

Switching Protocols and Monitoring

When switching between these medications, UK prescribers recommend close monitoring for the first 8-12 weeks. Weight should be tracked weekly, and any new side effects reported promptly. Most patients tolerate the transition well, though some experience temporary changes in appetite control or gastrointestinal symptoms during the adjustment period. Your prescriber may schedule follow-up consultations at 4 and 12 weeks post-switch to optimise dosing and ensure the new medication effectively maintains your weight loss without problematic adverse effects.

Long-Term Maintenance: Lifestyle Factors and Medication

Whilst maintenance doses of Wegovy or Mounjaro provide pharmacological support for weight management, sustainable results require ongoing attention to diet, physical activity, sleep, and stress management. These medications work most effectively when combined with behaviour modifications that support metabolic health [1].

UK clinical guidelines emphasise that GLP-1 receptor agonists are adjuncts to, not replacements for, lifestyle interventions. Patients who maintain regular physical activity, consume nutrient-dense diets with appropriate calorie intake, and prioritise sleep quality typically require lower maintenance doses and experience better long-term outcomes than those relying solely on medication.

Your maintenance strategy should be reviewed regularly with your UK prescriber, typically every 3-6 months initially, then annually once stable. These reviews assess weight trends, side effects, metabolic markers, and whether dose adjustments or additional support services might optimise your long-term success. At Cured Pharmacy, our clinical team provides ongoing support throughout your maintenance journey, ensuring you have access to evidence-based guidance whenever needed.

When to Consider Dose Adjustments

Several scenarios may prompt maintenance dose adjustments. If your weight increases by more than 3-5% over 2-3 months despite good lifestyle adherence, increasing the dose may be appropriate. Conversely, if you experience persistent side effects that impact quality of life, dose reduction whilst monitoring weight closely may be warranted. Life changes such as increased physical activity, dietary improvements, or resolution of medical conditions affecting metabolism might also allow for lower maintenance doses. Regular communication with your prescriber ensures your maintenance strategy evolves appropriately with your changing circumstances and needs.

Scientific References

1. Garvey, W. T., et al. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2473-2481. https://doi.org/10.1038/s41591-023-02532-4 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Aronne, L. J., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38-48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or adjusting your treatment plan. Weight loss results vary between individuals and depend on multiple factors including diet, exercise, and adherence to prescribed treatment protocols.